Who Manages SIADH?
SIADH is managed by the primary treating physician (internist, hospitalist, or general practitioner) in collaboration with specialists depending on the underlying cause—pulmonologists for lung disease, oncologists for malignancy, neurologists for CNS pathology, and endocrinologists for complex or refractory cases. 1
Primary Management Team
The initial diagnosis and treatment of SIADH typically falls to the admitting or primary care physician, who must first confirm the diagnosis through clinical and laboratory assessment, then initiate fluid restriction and address reversible causes 2, 3. For hospitalized patients with moderate to severe hyponatremia (sodium <125 mmol/L), management should occur under close inpatient monitoring with frequent sodium checks 1.
Specialist Involvement Based on Etiology
Oncology Consultation
Malignancy-related SIADH requires oncology involvement, particularly for small cell lung cancer (the most common malignant cause, occurring in 10-45% of SCLC cases) and other tumors producing ectopic ADH 4, 5. Treatment of the underlying malignancy is essential alongside hyponatremia management, as successful cancer treatment often resolves the paraneoplastic syndrome 1, 4.
Pulmonology Referral
Pulmonologists should manage SIADH secondary to non-malignant lung disease, including pneumonia, tuberculosis, and other pulmonary infections 4. A chest radiograph or CT scan is recommended as part of the initial workup for newly diagnosed SIADH to identify pulmonary causes 3.
Neurology/Neurosurgery Consultation
Neurologists or neurosurgeons must be involved when SIADH results from CNS pathology—including infections, space-occupying lesions, subarachnoid hemorrhage, or other neurological diseases 4. Critically, these specialists must distinguish SIADH from cerebral salt wasting (CSW), as the two conditions require opposite treatment approaches (fluid restriction for SIADH versus volume replacement for CSW) 1, 4.
Endocrinology Referral
Endocrinologists should be consulted for refractory or complex cases, particularly when:
- Fluid restriction fails or is poorly tolerated 6
- Pharmacologic therapy (demeclocycline, vaptans) is being considered 1, 6
- Differential diagnosis is challenging (excluding hypothyroidism and adrenal insufficiency) 4
- Chronic SIADH requires long-term management strategies 7, 6
Intensive Care Involvement
Patients with severe symptomatic hyponatremia (sodium <120 mmol/L with altered mental status or seizures) require ICU admission for administration of 3% hypertonic saline, with serum sodium monitoring every 2 hours initially 1, 2. The ICU team manages the critical correction phase, ensuring sodium does not increase faster than 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome 1, 6.
Medication Review and Pharmacy Consultation
A comprehensive medication review is essential, as multiple drug classes cause SIADH—including SSRIs, carbamazepine, oxcarbazepine, NSAIDs, opioids, and chemotherapy agents (platinum-based, vinca alkaloids, cyclophosphamide) 4, 7, 5. Discontinuing offending medications is a critical first step that may resolve SIADH without further intervention 1.
Common Pitfalls in Management Coordination
- Failing to identify and treat the underlying cause leads to persistent SIADH despite symptomatic treatment 1
- Misdiagnosing CSW as SIADH in neurosurgical patients results in inappropriate fluid restriction that worsens outcomes 1, 4
- Inadequate monitoring during active correction risks osmotic demyelination syndrome 1
- Not involving oncology early in patients with known or suspected malignancy delays definitive treatment 4